Catalio Capital Management Research
Investment Thesis
Catalio Capital Management is a New York-based investment firm focused on the full lifecycle of innovative healthcare investing, across private, public, and credit markets. Founded in 2020 by George C. Petrocheilos and R. Jacob Vogelstein, Ph.D., the firm invests in category-defining healthcare businesses spanning drugs, devices, diagnostics, data, and AI-enabled digital tools that bend the cost curve and redefine patient care. Catalio's differentiating edge is a network of 45+ Venture Partners, an elite group of world-renowned, serial scientist-entrepreneurs who provide proprietary deal flow, rigorous scientific due diligence, and early exposure to breakthrough biomedical technologies. The firm states that 79% of VC funds raised since 2020 have returned $0 to investors, while Catalio has distributed nearly $300M to investors over the same period from its Funds and SPVs.
Sector Focus
Catalio invests exclusively in healthcare and biomedical technology. Its stated portfolio breakdown spans Drugs, AI-Enabled healthcare, Devices, Diagnostics, and Others, reflecting a thesis that spans traditional biotech/life sciences alongside AI-enabled digital health and diagnostics. It explicitly frames its focus as "healthcare x AI."
Stage Focus
Across its Private Equity strategy, Catalio invests in privately held innovative healthcare companies "at all stages, from inception to IPO." In practice this spans seed/early venture rounds (e.g., Series B/C co-investments) through growth and pre-IPO structured financing, plus public equities post-IPO.
Check Size
Check size varies significantly by strategy. Secondary sources put the average venture check around $15M. Recent disclosed deal sizes include a $20M credit investment (Amalgam Rx), a $70M Series C participation (Ratio Therapeutics), a $118M Series B co-lead (Claris Bio), and a $275M PIPE (Entera Bio) — the latter two reflecting Catalio's broader credit and public-equities capacity rather than a single VC check.
Lead Tendency
Catalio both leads and co-leads early-stage rounds (e.g., co-led Atai Life Sciences' 2020 Series C, co-led Claris Bio's 2026 Series B) and participates in larger syndicated rounds alongside investors like Eli Lilly, Bristol Myers Squibb, Peter Thiel, and Christian Angermayer (e.g., Ratio Therapeutics' Series C).
Recent Activity
Catalio closed its fourth venture fund with over $400M in commitments (announced July 2025) and its Structured Opportunities credit strategy has raised at least $325M (per third-party reporting). As of October 2025, the firm reported $2B in assets under management. Recent activity (mid-to-late 2026) includes: Superluminal Medicines' oversubscribed $60M Series B (Sep 2026); recognition on TIME's list of America's Top Venture Capital Firms (Aug 2026); participation in Ratio Therapeutics' $70M Series C (Aug 2026); co-leading Claris Bio's $118M Series B (Jul 2026); supporting Entera Bio's $275M PIPE (Jul 2026); the $3.8B Eli Lilly acquisition of portfolio company Atai Life Sciences (Jul 2026); Kardigan's $460M Nasdaq IPO (Jun 2026); and Parabilis Medicines' record-setting $670M IPO, the largest in the sector's history (Jun 2026).
Portfolio Highlights
Catalio's portfolio spans 100+ healthcare companies. Notable exits and public listings include Atai Life Sciences (IPO 2021; acquired by Eli Lilly for $3.8B, 2026), Recursion (IPO 2021), Compass Pathways (IPO 2020), Neumora Therapeutics (IPO 2023), ArriVent (IPO 2024), Dianthus (IPO 2024), Kardigan (IPO 2026), Parabilis Medicines (formerly FogPharma, IPO 2026), Haystack Oncology (exit 2023), Personal Genome Diagnostics/PGDx (exit 2022), and Paige AI (M&A 2025). Active portfolio companies include Abridge, Hippocratic AI, OpenEvidence, Recursion, Lila Sciences, Singular Genomics, Sherlock Biosciences, and Freenome, among many others across drugs, devices, diagnostics, and AI-enabled healthcare software.
Team
Catalio was co-founded by George C. Petrocheilos and R. Jacob Vogelstein, Ph.D., who serve as Co-Founder & Managing Partners. The investment team includes partners leading each strategy: Diamantis Xylas, M.D. (Partner & Co-Head of Private Equity), Isaac Ro (Partner), John Henry Iucker, CFA (Partner & Head of Credit), Ben Snedeker (Partner & Head of Public Equities), Olga Maltseva (Partner & Head of Operations), Tom Brooks (Partner), Ajay Mantha (Partner), and Hai Yan, Ph.D. (Partner). The firm also maintains a Board of Advisors including Henry Kravis (Chairman), Orlando Bravo, Jim Breyer, Glenn Dubin, Isabelle Ealet, and Alex Gorsky, plus a network of 45+ Venture Partners composed of world-renowned scientist-entrepreneurs such as George Church, Ph.D., Frances H. Arnold, Ph.D., David Sinclair, Ph.D., and Bert Vogelstein, M.D.
Decision Process
With a multi-partner structure across Private Equity, Structured Opportunities, Public Equities, and Co-Investments, and a Board of Advisors and formal Venture Partner network feeding scientific diligence, Catalio operates as a partnership rather than a solo-GP or narrow investment-committee model.
Founder Preferences
Catalio backs "world-class founders": world-renowned serial entrepreneurs building companies with transformative technology, strong IP, and the ability to recruit experienced management teams and strong financial syndicates.
Geographic Focus
Catalio is headquartered in New York City, with additional offices in Washington, DC and London, and 40+ employees globally. Its investment focus is not geographically restricted within healthcare innovation, with portfolio companies across the US and Europe.